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Abstract 
The vertebrate immune system is an enormously complex arrangement of a large number of 
interdependent cell types, responsible for fending off harmful invasive organisms as well as 
aberrant cells within the host itself. The system is divided into two broad arms; the innate and 
the adaptive immune compartments.  
Whereas the cells of the innate arm recognizes threats based on certain characteristics 
common to most invaders, adaptive immune cells is able to recognize billions of unique 
antigens due to specialized receptors on their surface. This ability is dependent on an efficient 
means of exposing the cells to antigenic peptides, achieved through a mechanism known as 
antigen presentation. Several cell types, commonly referred to as professional antigen 
presenting cells (pAPCs), are able to carry out this function; most well known of these are the 
dendritic cells (DCs). However, difficulties in growing DCs in vitro has led to an increased 
interest in using alternative APCs to expand robust adaptive immune responses for clinical 
use. By using CD40 activated B cells as an alternative APC, we observed a significant 
difference in T cell expansions towards specific antigens.   
Efficient antigen presentation requires the two distinct immune compartments to act in 
unison, where cell-mediated lysis carried out by the innate system generate antigenic peptides 
for activation of adaptive responses. Natural killer (NK) cells are innate immune cells, 
capable of eliminating virus infected or cancer-transformed cells without prior activation, an 
ability that coined the term “natural killer”. NK cells are regulated through signaling from a 
diverse array of activating and inhibiting receptors, with stress proteins acting as ligands for 
the activating receptors, and MHC molecules generally acting as ligands for inhibitory 
receptors. In this thesis we hypothesized that NK mediated cytolysis can bridge innate and 
adaptive immunity and prime systemic T cell reactivity. NK cells are able to respond quickly 
to cells that express stress markers, or lose expression of MHC molecules, characteristics that 
are generally associated with malignancy. It is possible that this innate recognition of 
transformed cells contributes to a more efficient priming of adaptive immune responses by 
generating peptide fragments readily available for presentation to T cells.  
Using a step-wise in vitro model system of T cell priming we found evidence of improved T 
cell expansions as a result of being stimulated with peptide fragments obtained through NK 
cell mediated cytolysis of a melanoma cell line. This stimulation also led to an increase in 
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epitope specific cells against a known melanoma antigen, MART-1. Although further 
investigations are needed, exploiting NK cell cytolysis and natural fragmentation of tumor 
associated antigens may hold utility in the development of cancer vaccines by providing new 
insights into tumor specific epitopes and neo-antigens. 
 
 
 
 
 
 
 
  
VII 
 
Acknowledgements 
This project was carried out in Karl Johan Malmberg’s group at the Department of 
Immunology at Oslo Radium Hospital. I would like to give a sincere thank you to Kalle for 
giving me the opportunity to be a part of his group, for his guidance and council, and for the 
proofreading of this thesis. You are an excellent and patient boss. 
 Massive thanks goes out to my brilliant supervisor and Australian friend, Jodie Goodridge, 
who has been an invaluable help in every part of the process. You always had a solid answer 
to my rookie questions, and you never got visibly frustrated over my mistakes. Your patience 
and understanding is truly admirable. You even gave me hope that Half-Life 3 will be 
released in my lifetime. I would never have been able to do this without you. 
Thank you to all other members of the Malmberg group: Eivind, Kishan, Vincent, Benedict, 
Merethe, Julie, Michelle, Axel and Trevor. You are all excellent people. Your presence 
creates a welcoming environment, and I was always able to find someone to talk to, be it 
about immunology or the latest viral Youtube video.  
I would also like to thank my girlfriend Camilla, who found the time to help me proofread, 
even while working on her own master thesis. Thanks to my friends, who at least somewhat 
tried to refrain from drinking too much beer while I was at home writing. 
And also, thanks to my mom, who corrected my grammar. Hopefully it were’nt to bad (wink). 
 
Oslo, May 2015 
Tarjei Nevestveit 
 
VIII 
 
 
 
 
 
  
IX 
 
 
X 
 
Table of Contents 
Summary ................................................................................................................................... V 
Acknowledgements ................................................................................................................. VII 
1 Introduction ........................................................................................................................ 1 
 The immune system ..................................................................................................... 1 
1.1.1 The innate immune system ................................................................................... 1 
 The adaptive immune system ...................................................................................... 3 
1.2.1 Antigen presentation ............................................................................................ 3 
1.2.2 Cross-Presentation ................................................................................................ 4 
1.2.3 B cells ................................................................................................................... 5 
1.2.4 T cells ................................................................................................................... 6 
 Natural Killer cells ....................................................................................................... 7 
1.3.1 NK cell education ................................................................................................. 8 
1.3.2 NK cell differentiation ....................................................................................... 11 
 Summary in regards to the generation of immune functions..................................... 12 
 Description of project ................................................................................................ 13 
 Relevance of project .................................................................................................. 15 
2 Materials and Methods ..................................................................................................... 18 
 Flow Cytometry ......................................................................................................... 18 
 Staining cells.............................................................................................................. 19 
2.2.1 Tetramer staining ................................................................................................ 20 
 Cell lines .................................................................................................................... 20 
2.3.1 NIH-3T3 tCD40L ............................................................................................... 20 
2.3.2 NK cell lines ....................................................................................................... 21 
 Cytotoxicity assay...................................................................................................... 21 
2.4.1 Time based Degranulation assay ........................................................................ 22 
2.4.1 Fractionation of Lysates ..................................................................................... 22 
 Cell storage ................................................................................................................ 22 
2.5.1 Freezing cells ...................................................................................................... 22 
2.5.2 Thawing cells ..................................................................................................... 23 
 Culturing CD40 activated B cells .............................................................................. 23 
2.6.1 AutoMACS separation ....................................................................................... 23 
XI 
 
 B cell culture .............................................................................................................. 24 
2.7.1 Pulsing with antigen ........................................................................................... 24 
2.7.2 Antigenic peptides used to pulse cell cultures ................................................... 25 
2.7.3 Pulsing with tumor cell Lysate fraction ............................................................. 26 
 T cell culture .............................................................................................................. 26 
2.8.1 Media and supplements ...................................................................................... 27 
3 Results .............................................................................................................................. 28 
 Establishing a B cell APC system for robust T cell responses .................................. 28 
3.1.1 CD40 activated B cells exhibit a substantial increase in CD86 expression ....... 28 
3.1.2 Activated B cells were co-cultured with autologous PBMC and pulsed with 
antigen peptide libraries to induce expansion of T cells. ................................................. 29 
 Expansion of T cells in response to antigens ............................................................. 31 
3.2.1 Co-culturing with CD40 activated B cells results in increased T cell expansions
 33 
 Generation of epitope specific T cell responses ........................................................ 36 
3.3.1 CD8+ T cell specific expansions towards PP65 antigen..................................... 36 
 Generation of NK derived cytolytic fragments for antigen presentation .................. 39 
3.4.1 NKL exhibits a stronger degranulation than NK92 versus FemX ..................... 39 
3.4.2 CD40 activated B cells has a significant effect on CD8+ T cell expansions 
pulsed with lysate resulting from NK cytolysis ............................................................... 42 
3.4.3 Pulsing with melanoma cell lysate induces expansion of MART-1 specific CD8+ 
T cells 44 
3.4.4 MART-1+ tetramer specific CD8+ T cells are predominantly central memory 
cells 46 
4 Discussion ........................................................................................................................ 48 
 Cell handling: A lesson in care .................................................................................. 50 
 Concluding remarks ................................................................................................... 51 
References ................................................................................................................................ 53 
 
  
XII 
 
Figure 1 Schematic view of cross-presentation. ......................................................................... 5 
Figure 2 NK cell education models ............................................................................................ 9 
Figure 3 Differentiation of NK cells. ....................................................................................... 12 
Figure 4 A Flowchart illustrating the main steps of the project. .............................................. 14 
Figure 5 A representation of the expression of B cell activation marker CD86 over time ...... 29 
Figure 6 Plate set up for pulsing cells with antigen. ................................................................ 30 
Figure 7 Example of the gating strategy used for analysis of T cell expansions. .................... 32 
Figure 8 Graph of expansions in CD4+ and CD8+ T cells, represented by fold change. ........ 35 
Figure 9 The result of the screen for HLA-A2 positive donors. .............................................. 37 
Figure 10 Tetramer stains of donor 206. .................................................................................. 38 
Table 1 Percentages of tetramer positive CD8 T cells. ............................................................ 38 
Figure 11 Gating strategy for the CD107a degranulation assays. ............................................ 40 
Figure 12 Results of the degranulation assays ......................................................................... 41 
Figure 13 Shows expansions of CD8+ T cell pulsed with FemX lysate. ................................. 43 
Figure 14 MART-1 tetramer specific CD8+ T cells. ............................................................... 45 
Figure 15 Determination of differentiation state of MART-1 tetramer+ CD8+ T cells. ........... 46 
Figure 16 Levels of CD62L expression in the MART-1 positive and negative CD8+ 
populations. .............................................................................................................................. 47 
 
 
 
  
1 
 
1 Introduction 
 
 The immune system 
The vertebrate immune system is composed of various structures and processes dedicated to 
defend the body against harmful foreign invaders or abnormal internal behavior. It 
encompasses a well-organized army of specialized cells, as well as structural barriers to 
prevent any harm to the host. A distinctive feature of the vertebrate immune system, as 
opposed to invertebrates, is the sub classification into the innate and the adaptive immune 
system[2]. Innate immunity is common to all species, both plants and animals as well as 
fungi, and is in terms of evolution a more primitive system that responds to infecting agents, 
known as pathogens, in a generic and highly consistent  manner. Adaptive immunity is 
generally considered a feature of vertebrates, although there is evidence of a similar system 
present in some non-vertebrate species[3]. The focus of this project is on the cells and 
mechanisms of the vertebrate system however, which have the ability to respond to specific 
pathogens, mount an effective response, and then remember that pathogen to quickly respond 
to subsequent infections.  
1.1.1 The innate immune system 
The first obstacle a pathogen encounters as it tries to enter the body is the epithelial surfaces 
lining the parts of the body that are in direct contact with the environment. These form a 
physical barrier that efficiently blocks entry for most infectious agents[4]. Peristalsis and 
ciliary movement in the gastrointestinal and respiratory tract help removing invaders that 
become trapped on these surfaces. In addition, mucus, gut flora, tears, and saliva, all help in 
removing foreign invaders [4].  
Some pathogens are still able to bypass these barriers however, causing infection. One of the 
first responses to infection is inflammation, leading to the classical signs of heat, pain, 
redness, swelling and loss of function. Inflammation is initiated by cells of the innate immune 
system, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and 
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mastocytes. These cells release various chemicals that mediate the inflammation, and recruit 
other cells of the immune system to the infected area.  
Innate immune cells express germline-encoded pattern recognition receptors (PRRs) that 
recognize various molecular signatures found only on pathogens, known as pathogen-
associated molecular patterns (PAMPs). These moieties include lipopolysaccharides found on 
bacteria, hydrophobic lipids and proteins, as well as nucleic acids associated with viruses such 
as 5’triphosphate RNA[5]. There are several classes of PRRs, most extensively studied of 
these are perhaps the Toll-like receptors (TLRs), of which ten have been identified in 
humans[6].  
Cells of the innate system are classified as white blood cells, known as leukocytes, that 
circulate in the blood stream searching for invaders. Most innate leukocytes are unable to 
divide or reproduce on their own, but are differentiated from hematopoietic stem cells in the 
bone marrow[7]. The innate leukocytes include mast cells, eosinophils, basophils, 
macrophages, neutrophils, dendritic cells and natural killer (NK) cells[2]. These cells are able 
to respond quickly to invasive pathogens, but the magnitude of the response is limited and 
does not vary between first and subsequent encounters. This is in contrast to the response 
profile of the adaptive immune system, which is slow in primary infection, but increase in 
scope and effectiveness during secondary infections due to generation of pathogen specific 
memory cells[8].  
Some innate cells are classified as lymphocytes, the main cell type found in the lymphatic 
system. Recently, the family of innate lymphocytes has grown considerably, with the 
classification of innate lymphoid cells (ILCs); defined by a lack of rearranged antigen 
receptor genes, a lack of myeloid and dendritic cell phenotypical markers, and having a 
lymphoid morphology. The ILC family includes ILC1, ILC2, ILC3 and MAIT cells. Of 
special significance to this project are natural killer (NK) cells, which are a part of the ILC1 
group, characterized by the production of interferon-γ (IFN- γ) and an inability to produce 
TH2 and TH17-cell associated cytokines[9]. The rather descriptive name of “natural killer” 
stems from the ability of these cells to quickly respond to and kill cells that have lost their 
“self” markers, MHC class I molecules, without activation[10]. NK cells will be described in 
more detail in section 1.3.  
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 The adaptive immune system 
Unique recognition of billions of different types of molecules is the defining ability of the 
adaptive immune system[2]. Being able identify not only dangerous foreign molecules as 
something that must be eliminated, but also the body’s own materials as something that must 
be ignored, is both an accomplishment of evolution as well as crucial prerequisite for survival. 
This ability is obtained through a complex mechanism of random rearrangements in the genes 
coding for antigen receptors in the cells of the adaptive immune system, and the presentation 
of small peptide fragments called antigens, obtained through the destruction of invasive 
organisms[2, 11-14].  
1.2.1 Antigen presentation 
Antigens are presented to the immune system by two classes of molecules on the surface of 
the presenting cell, the MHC class I and MHC class II. These two molecules are similar, but 
have some important differences[15]. Firstly, they differ in the origin of the peptides 
presented. Class I molecules present antigens originating in the cytosol of the cell, while 
material picked up from the extracellular environment and broken down in the cell will be 
presented on MHC class II. A consequence of this difference is that MHCII is present on a 
much more limited selection of cell types than MHCI. Class I molecules are expressed on all 
cells in the human body with the exception of red blood cells. Peptide fragments from every 
protein produced by the cell are constantly presented on class I, and monitored by a type of 
adaptive lymphocytes called T cells[16]. When a cell is producing abnormal proteins as a 
result of an infection or mutation, it will be detected by the immune system through 
presentation on class I, and the cell will be eliminated. Class II however, is present mainly on 
cell types that are able to pick up invasive antigens from the environment and eliminate them, 
in other words mostly immune cells – dendritic cells, macrophages, B cells, T cells, and 
thymic cortical epithelial cells[2, 17]. The two classes of MHC molecules present their 
antigens to different co-receptors on T cells, CD4 and CD8. The presence of these co-
receptors defines two major subtypes of T cells, cytotoxic (CD8) and helper (CD4) T cells. 
CD8 recognizes antigens presented on class I, and if identified as a foreign peptide, cytotoxic 
T cells will destroy the affected cell[18]. MHC II presents antigens to the CD4 found on 
helper T cells. Antigens displayed on class II molecules are derived from extracellular sources 
– usually as a result of a breakdown of invading pathogens, which are processed inside the 
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immune cell and transported to the MHCII to be presented on the cell surface[15]. Here they 
are recognized by CD4 positive helper T cells, which then in turn are activated and further 
drive the immune response to be more efficient versus this pathogen.   
1.2.2 Cross-Presentation 
Generally, MHC class I presents antigens derived from the intracellular environment, and 
MHCII present extracellular antigens. However, if this rule was strictly adhered to with no 
exceptions, the immune system would not be able to function. Naïve T cells need to be 
primed through interactions with professional antigen presenting cells (pAPCs), after which 
they will mediate infector function when they recognize the same antigen on an infected or 
transformed cell. In general, foreign antigens are presented on MHCI when the cell is 
infected, and an activated CD8 T cell recognizes the antigen and destroys the cell. However, 
if foreign antigen on MHCI is only presented by infected cells, and naïve T cells need to 
recognize a foreign antigen on an MHCI on an APC to become activated, then the APC would 
have to be infected to be able to present the antigen to activate the naïve T cell. Fortunately, 
this is not required, and this is where cross-presentation comes into play. Cross-presentation is 
an ability of professional APCs, in which antigens from all sources can be presented on both 
classes of MHC[19]. This means that APCs can ingest extracellular material, process it, and 
present it on MHCI, as well as on MHCII. Cross-presentation also occurs for endogenous 
antigens that normally would be loaded onto MHCI, meaning that they can also be presented 
on MHCII. This allows CD4 helper T cells to be activated towards pathogen derived 
intracellular antigens[20]. The mechanism behind cross-presentation is illustrated in Figure 1. 
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1.2.3 B cells 
B cells are vitally important lymphocytes of the adaptive immune system. Their primary 
functions are to produce specific antibodies against invasive pathogens, and to present 
antigens to other parts of the immune system, functioning as an antigen presenting cell (APC). 
In this project, we are mostly concerned with their function as APCs. 
Antigen is encountered by B cells, primarily in secondary lymphoid organs, and recognized 
by the B cell receptor (BCR) present on all B cells[22]. The BCRs affinity for a given antigen 
is directly proportional to the capacity of the B cell to present this antigen to T cells[23, 24]. 
When a pathogenic epitope is recognized by a BCR, the pathogen is internalized and 
processed inside the cell. Peptide fragments are then presented on MHC class II, or on MHC 
 
Figure 1 Schematic view of cross-presentation. 
 
 A) Endogenous proteins of either self or pathogen origin are degraded into peptides and 
transported into the ER by TAP molecules for loading on MHC I molecules. B) Extracellularly 
derived proteins are endocytocytosed into the cell and presented on MHC II. C) APCs are able to 
take endocytosed antigens and load them onto MHC class I molecules for presentation to CD8+T 
cells, as well as load endogenous proteins onto MHC class II molecules for presentation to CD4+T 
cells. Figure adopted from [21] 
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class I through the cross-presentation mechanism described in 1.2.2.  The processing of the 
epitopes bound to the receptor is blocked, causing these regions of the antigen to be 
presented[25, 26], thus shaping the immune response towards these epitopes.  
However, as with most things in immunology, it is not as straight forward as it may seem at a 
first glance. A naïve B cell encountering a new antigen will not be allowed to instantly start 
initiating immune responses without confirmation that this antigen should be eradicated by 
the immune system. If the antigen is derived from a protein the B cell requires signals from 
CD4 T cells that recognize the same antigen to induce antibody responses. Without signals 
from the T cell, the B cell will not be able to induce a response. These antigens are known as 
thymus dependent, or TD antigens. The signal delivered by the CD4 T cell is sent when the T 
cell recognizes a peptide bound to MHCII on the B cell surface. CD40 ligand (CD40L or 
CD154) on the T cell interacts with CD40 on the B cell and contributes an essential part of the 
activating signal[27]. This interaction increases B cell proliferation, immunoglobulin class 
switching, somatic hypermutation, and an increase in expression of co-stimulatory molecules,  
most notably CD80 (B7-1) and CD86 (B7-2)[28]. Additional signals are delivered from the T 
cell in the form of secreted cytokines, IL-4 being one of the most important. Together with 
CD40 signaling, IL-4 is thought to drive the clonal expansion of B cells that precedes 
antibody production in vivo[29]. In this project, B cells are co-cultured with adherent feeder 
cells expressing CD40L, while at the same time being stimulated with IL-4. These conditions 
should maximize their antigen presenting potential. 
1.2.4 T cells 
T cells are the other major part of the adaptive immune response, the first being B cells. 
Similar to B cells, they express membrane bound receptors, known as T Cell Receptors 
(TCRs), capable of recognizing a staggering amount of different antigen epitopes[30, 31]. 
These highly variable receptors are the basis for adaptive immunity, as a cell expressing a 
receptor specific for an invading pathogen will be stimulated through various signals to 
duplicate and differentiate into various types of effector cells depending on the manner of 
antigen that is recognized. The two main families of T cells are known as CD4 T cells and 
CD8 T cells, classified by which class of MHC bound to a peptide they recognize. CD8 cells 
recognize peptides bound on MHC class I, and differentiate into cytotoxic effector cells that 
kill infected cells. CD4 cells recognize peptides bound on MHC class II, and can differentiate 
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into several distinct effector subsets, including multiple subsets of helper T cells and 
regulatory T cells[32]. Helper T cells are absolutely crucial for efficient activation of the 
adaptive immune system, including priming of B cells, while regulatory T cells inhibit 
undesirable immune activity such as self-reactive cells.    
Similar to the way naïve B cells are dependent on T cells for activation, naïve T cells require 
signals from antigen presenting cells such as B cells or dendritic cells before they are allowed 
to carry out their effector functions. A naïve T cell requires three different types of signals to 
be activated[33]. The first of these is the signal that results from interaction between the 
MHC:peptide complex with the TCR. This signal is essential, but not sufficient for the T cell 
to become fully activated. Additional signaling from an APC is required. This signaling can 
be divided into co-stimulatory signals that promote the survival and expansion of T cells, and 
signals that contribute to the differentiation of the T cell into various effector subtypes[34].  
Co-stimulatory signaling is provided by ligation of B7  molecules (primarily CD80 and 
CD86) on the APC to the CD28 receptor on the T cell, which is necessary for optimal clonal 
expansion[34]. For CD4 cells in particular, the type of signal provided by different cytokines 
released by the APC causes various pathways of differentiation that produces different subsets 
of CD4 T cells to carry out various effector functions that depends on the nature of the 
antigen, and the environment of the cells involved. 
 Natural Killer cells 
As hinted by their name, natural killer (NK) cells have the ability to hunt down and eliminate 
foreign or abnormal cells in the body[35]. NK cells are innate immune cells, that are able to 
spontaneously respond to a target without prior sensitization, however their cytolytic activity  
does not differ in magnitude upon subsequent encounters with the same target. They are a 
crucial part of the innate immune system, where they function as cytolytic lymphocytes to 
directly induce lysis or apoptosis in virus infected cells or tumor cells. Despite their 
classification as a lymphocyte and their similarity to T and B cells, NK cells are not 
considered a part of the adaptive immune system, as they do not possess antigen specific 
surface receptors. Rather, they work in a complimentary manner to the adaptive system. 
Where the adaptive system responds to antigens presented on the MHC proteins on the 
surface of another cell, NK cells responds to a lack of the MHC class I proteins themselves 
[10], a state known as “missing self”[36-38]. Being able to respond to a lack of MHC I 
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expression is necessary, as certain viruses and cancers have developed ways to disrupt this 
expression to avoid detection by adaptive immune cells[35, 39]. However, the recognition of 
missing self molecules is not the only function NK cells serve in an immune response. NK 
cell-mediated killing of antigen expressing cells induces specific CD8+ T cell responses to the 
antigen through cross-presentation[40, 41], thus acting as a link between the innate and 
adaptive immune system. They are major producers of cytokines such as interferon- (IFN-
)[42], tumor necrosis factor  (TNF-)[43] and interleukin(IL)-10[44]. The secretion of 
cytokines is a crucial step in activating further immune responses, having an impact on the 
production of dendritic cells (DC), macrophages, and neutrophils[45, 46]. Especially 
important is the impact on DCs, which are able to internalize the lysis fragments that result 
from NK cell mediated killing, and present the antigens on MHC I molecules to CD8+T cells 
through cross-presentation[41], as well as to CD4+T and B cells through presentation on 
MHC class II. DCs and NK cells have a symbiotic relationship, where they reciprocally 
activate each other, providing positive feedback mechanisms for both[47-49]. IFN- released 
by NK cells when they are activated, can cause maturation of DCs[50]. DC activation often 
results in production of type I IFN and IL-18, which serves to prime NK cells and increase 
cytolytic effector function [51]. As DCs are in turn important activators of both B and T cells, 
NK cell stimulation serves as a means of activating both the humoral and the cell-mediated 
arms of the adaptive immune system[52].  
1.3.1 NK cell education 
One of the most characteristic features of NK cells is an array of surface receptors that can 
either stimulate (activating receptors) or dampen (inhibitory receptors) their activity [53, 54]. 
To prevent aggression from NK cells towards the cells of the host, a variety of receptors that 
recognize self molecules inhibit NK cell activity. The predominant mechanism are inhibitory 
receptors that recognize self  MHC I molecules. [55, 56]. However, NK cells lacking 
expression of inhibitory receptors will not react to all cells they encounter. This would lead to 
dramatic autoimmunity, and is prevented by a process known as NK cell education, where 
cells deficient for inhibitory receptors are rendered unresponsive[57, 58]. Several mechanisms 
behind this process have been proposed. Although each model has unique features, there are 
also many shared aspects between them, and their differences do not necessarily mean they 
are mutually exclusive and they could all be complementary biological processes involved in 
NK cell education.  
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Figure 2 presents and overview of the various models for NK cell education. The “licensing”, 
or “arming”[58], model suggests that NK cells only become responsive after encountering 
MHC class I on an inhibitory receptor[58], meaning that signals from inhibitory receptors 
promote maturation. This view is supported by studies that show immunoreceptor tyrosine-
based inhibitory motif (ITIM)-containing receptor based signaling can lead to 
phosphorylation of downstream signaling substrates [59, 60].  
 
Figure 2 NK cell education models 
 
 A) In the arming model, NK cells only become responsive after receiving a signal from 
an inhibitory receptor. B) The disarming model suggests that NK cells become 
unresponsive in the absence of an inhibitory receptor. C) Shows the cis-interaction 
model, where inhibitory receptors can interact with MHC molecules in their own 
membrane. D) The rheostat model proposes a more dynamic view of education, where 
the balance between inhibitory and activating signals determines the strength of the 
response. Figure adopted from [1] 
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The second model proposes a “disarming” hypothesis, where NK cells are rendered 
unresponsive by chronic stimulation by normal cells, unless opposed by inhibitory MHC I 
receptors[61]. This model suggests that NK cells are responsive in their initial state, and are 
rendered anergic by chronic stimulation, unless opposed by interactions with MHC I.   
The cis-interaction model is based on observations of Ly49, a class murine NK cell inhibitory 
receptors that bind MHCI, similar to human KIR receptors. The Ly49 receptors are able to 
bind MHCI molecules in cis, that is, in the same cell membrane [62-64]. This model suggests 
that cis interactions between MHC I and Ly49 receptors sequesters the Ly49 receptors and 
prevents them from relocating to the immunological synapse at the target cell interphase. This 
sequestering of unengaged inhibitory receptors decreases inhibitory signaling and increases 
the responsiveness of the NK cell [1].   
More recent studies have uncovered that NK cell effector function and responsivity are 
influenced by the number of inhibitory receptors they possess, with more receptors leading to 
higher activity levels[65]. The suggestion that NK cell education operates in a quantitative 
manner has been named the rheostat model [66]. Depending on the amount of inhibitory and 
activating signals it receives, the NK cell responsiveness can be tuned up and down [65, 67]. 
The rheostat model provides a framework, which is consistent with both the licensing and 
disarming models. It is also potentially mechanistically compatible with the cis-interaction 
model.  
The licensing and disarming models of NK cell education are as mentioned not necessarily 
mutually exclusive mechanisms, and it is possible that they both occur in different contexts. 
Tumors might create an environment of constant inflammation, a context in which NK cells 
could become overwhelmed by a constant barrage of stress activating ligands and rendered 
hyporesponsive[68]. Uneducated NK cells that lack inhibitory receptors have also been shown 
to be more effective than educated cells in certain circumstances, after having been provided 
with a strong activating receptor. These circumstances could be antibody-dependent cellular 
cytotoxicity (ADCC) against MHC I positive cancer cells, where uneducated cells equipped 
with the Fc receptor CD16 outperformed educated cells in cancer clearance[69]. Nevertheless, 
cancer-transformed cells tend to alter the expression of inhibitory ligands such as MHC I to 
prevent recognition from cancer reactive T cells, or present stress-induced activating ligands, 
making them ideal targets for NK cells[70, 71]. The most potent effectors against these targets 
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are CD56dim NK cells[72], which are more mature and are terminally differentiated from 
CD56bright cells[73]. 
1.3.2 NK cell differentiation 
So in what way does NK cell education manifest in the phenotype of the NK cell? The result 
is not as simple as a division into subsets of “educated” and “non-educated” NK cells. 
Traditionally, NK cells have been divided into two distinct subsets, defined by the amount of 
CD56 expressed on the cell surface, known as CD56bright and CD56dim, bright expressing a 
high amount and dim expressing a low amount[74]. These subpopulations may be divided 
further into distinct subsets based on their expression of various other molecules and receptors 
such as NKG2A/CD94, KIR, NKG2C, CD62L, and CD57[75-77]. As the NK cell receives 
signaling, it differentiates and acquires or loses expression of these receptors. Mature NK 
cells starts differentiation from CD56bright, who are not very cytotoxic but produce a lot of 
IFN-γ. As the cells differentiate, they lose some of their CD56 expression and move towards a 
CD56dim phenotype. These more mature CD56dim NK cells are more cytotoxic, but doesn´t 
generally produce as much IFN-γ. As the cells mature further, they acquire CD57. These 
CD56dim CD57+ are the most differentiated and are able to produce more IFN-γ when 
triggered by activating surface receptors[78]. NK cell differentiation together with the 
stochastic expression of a wide range of inhibitory receptors diversifies the human NK cell 
repertoire. A recent study identified several thousand distinct subpopulations of NK cells in 
the peripheral blood of humans[79]. This reveals the extremely complex nature of the NK cell 
role in the immune response, and it seems that we as of yet have barely scratched the surface 
of understanding their function. Figure 3 presents a flowchart of the maturation process for 
NK cells. 
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 Summary in regards to the generation of 
immune functions 
Natural killer cells are innate lymphocytes that are able to quickly respond to virus infected or 
cancer-transformed cells without activation, due to a vast array of inhibitory and activating 
receptors that recognize changes in expression levels of ligands for these receptors. Efficient 
NK cell mediated cytotoxicity generates peptide fragments from these threats, which can in 
turn be taken up, processed, and presented to the adaptive immune system by antigen 
presenting cells (APCs). In this manner, NK cell acts as a mediator between the innate and 
adaptive immune compartments by providing the antigenic peptides required for adaptive 
recognition.  
B cells, though mostly regarded as producers of antibodies, are also highly efficient APCs, 
able to internalize the antigenic peptides generated through NK cytolysis of targets, and 
present target specific antigens to CD4 T cells on MHC II, and also to CD8 T cells through 
cross-presentation on MHC I. This allows for priming of antigen specific T cells, which will 
divide and proliferate resulting in an expansion of T cells able to recognize the target through 
various epitopes. 
Figure 3 Differentiation of NK cells.  
 
Shows the progression from CD56bright (1) to CD56dim CD57+ (8) with discrete stages in 
between. Note how NKG2A is both acquired and lost through the various stages. Figure by 
Jodie Goodridge 
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By using target cell lysate resulting from NK cell mediated toxicity, the hypothesis that 
motivated this project states that more epitopes should become available for presentation, 
resulting in efficient T cell expansions. 
 Description of project 
The main focus of this project was to elucidate the molecular mechanisms that connect NK 
cell mediated lysis to generation of adaptive immune responses and memory, using a 
combination of the most current techniques in molecular biology, genetics, cell biology and 
flow cytometry. To approach this goal, a general 4-step process was used. First, target cell 
lines were destroyed through cytolysis. The lysates resulting from this were fractionated and 
then pulsed onto antigen presenting cells (APCs). These APCs were then used to generate 
adaptive T cell responses against the target cell line. Figure 4 is an illustration representing the 
general process. 
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A-C. Killing of target cells 
Using NK cells to kill target cells generates a lysate containing peptide fragments from the 
target cell line. This lysate can then be separated into discrete fractions containing peptides of 
a given size. Peptides of sizes between 3kD and 10kD can be used, as these are of 
theoretically ideal size for antigen presentation versus spontaneous formation of MHC 
complexes on the cell surface with smaller peptides of 1kD or less. 
Figure 4 A Flowchart illustrating the main steps of the project. 
 
 A) NK cell destroying a target cell. B) The target cell is broken into fragments as a result of NK 
cytolysis. C) The cell lysate is filtered into size based fractions. D) the 3kD-10kD fraction is pulsed 
onto B cells, which will present them to T cells. E) Expansion of T cell specific for the target cell. 
Figure by Jodie Goodridge. 
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D. Presentation of antigens 
Lysates from the previous step are pulsed onto antigen presenting cells (APCs), for cross-
presentation on MHC class I to CD8+ T cells. B cells co-cultured with adherent feeder cells 
expressing CD40L serve as APCs in these experiments. Co-culturing B cells with CD40L in 
combination with IL-4 leads to upregulation of expression of MHC class I and class II 
molecules, as well as the co-stimulatory molecules CD80 and CD86, which will enhance 
antigen presentation capabilities of the B cells. The expression levels of these molecules will 
be monitored over time. 
E. T cell expansion 
When a naïve T cell recognizes its cognate antigen, it needs stimulation from an APC to 
multiply. In this experimental layout, the CD40 activated B cells provide this stimulation. In 
the project, T cell cultures that have and have not been co-cultured with such B cells have 
been compared. The hypothesis is that the B cells provide a more efficient means of 
displaying antigen and therefore driving greater expansion of T cells versus PBMC alone. 
Cultures stimulated with peptide libraries of known antigenic peptides were compared to cells 
stimulated with the lysate fraction resulting from NK cell cytolytic activity. Pulsing with the 
lysate fraction should theoretically provide additional antigens toward a specific target that 
are not a part of the peptide libraries, which should result in improved T cell expansions. 
E. Evaluating the nature of expanded T cells 
A more detailed look at the biology of the expansions can be provided by looking at memory 
cell responses using fluorescently labelled antibodies toward CD45RA, CD45RO and CD67L. 
Tetrameric MHC molecules are used to assess their specificity towards the antigens presented 
to them.   
 Relevance of project 
The ability to generate immune responses tailored against specific diseases has over the last 
few decades become increasingly relevant, with the advent of immunotherapy[80-85]. 
Harnessing the power of the body’s natural defense mechanisms has the potential to help 
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combat some of the most widespread serious and deadly diseases, like cancers and 
autoimmune disorders, as well as infections of various pathogenic organisms. However, a 
solid understanding of the mechanisms involved in priming the immune system is required in 
order to maximize efficiency and minimize risks. This project aims to contribute to this 
understanding, by focusing on the early steps bridging innate immune responses to the 
priming of systemic immunity in the host.  
An important part of the project is using antigen-presenting cells (APCs) to prime immune 
responses to various antigens. The APCs used will be B cells – most commonly known as 
antibody producers, but B cells are also highly efficient APCs[22, 86]. Activated APCs have 
been grown before, and used in clinical trials, but the focus has mainly been on using 
dendritic cells (DCs) [87-90]. While DCs are excellent APCs, they are difficult to expand in 
vitro, and are required to be in a specific differentiation state to exhibit antigen-presenting 
capabilities. The realization that B cells are capable of presenting specific antigens to generate 
immune responses, has led to increased interest in their clinical applications [22, 91]. The 
method described in the project presents a relatively simple way of expanding purified, 
activated B cells, and looks at the response of T cells co-cultured with them. 
Activation of an immune response starts with the recognition of a foreign substance, known 
as an antigen (Ag). The origin of this antigen can be from a myriad of sources – viruses, 
bacteria, parasites are commonly known causes of immune responses – but can also originate 
from the body itself. Abnormal cells, like in cancer, that produce unusual proteins are for the 
most part swiftly taken care of and removed by the immune system[92, 93]. Unfortunately, 
sometimes this system fails, and allows the abnormal cells to live, and cancer can develop 
freely. So how can we strengthen the immune system to respond in these situations? 
Addressing this challenge is the focus of the field of immunotherapy. In this project, Natural 
Killer (NK) cells will be utilized to kill target cancer cell lines. As a result of this, the cell will 
be destroyed, leaving behind a fragmented profile of what the cell contained. These fragments 
will then be captured by activated B cells, and the B cells will then process and present these 
fragments as antigens to T cells. Hopefully, this will provide an efficient method for mass 
production of highly specific T cells toward the target cell. 
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2 Materials and Methods 
 
 Flow Cytometry 
The principle behind flow cytometry is fluorescent labels, known as fluorophores, attached to 
antibodies specific for various cell markers. The antibodies bind their targets on the cells, a 
cell suspension is run through the flow cytometer, where lasers with different wavelengths 
excite the fluorophores, and the intensity of the resulting fluorescence is measured for each 
cell to determine the quantity of markers present. In addition to the information gathered from 
the fluorescence, the cytometer can also measure the physical properties of each cell, based on 
their interaction with the laser. From this interaction, information about size and internal 
complexity can be obtained. These physical properties are often characteristic of specific cell 
populations, and are very useful for sorting out unwanted material, such as dead cells or 
debris.  
A flow cytometer has five main components[94]: 
 -A flow cell, which ensures the cells pass in a single file through the light beam.  
 -A measuring system, usually based on conductivity and optical properties.  
 -A detector and a system that converts light into electrical output that can be processed 
by a computer.  
 -An amplification system that strengthens the resulting signals. 
 -A computer to process the data. 
Flow cytometry can also be used to determine the amount of specific T cells, by staining with 
fluorescently labelled tetrameric MHC molecules. A tetramer is made up of four MHC 
monomeric molecules, bound together by a streptavidin. Tetrameric MHC molecules, as 
opposed to monomeric molecules, are used because monomeric MHC molecules have a high 
dissociation rate from T cell receptors. By using four MHC monomers bound together as a 
tetramer using streptavidin, each individual MHC molecule can bind a TCR, and in this way 
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increase the binding avidity. Tetramers are made up of four genetically engineered MHC 
molecules that have had a part of them replaced by a biotinylated domain, and have been 
stimulated with a peptide of interest. The MHC molecules are then mixed with streptavidin 
marked with fluorophore, and the biotinylated domains on the MHC molecules bind to the 
streptavidin, and form tetramers. These can then form complexes with TCR specific for the 
antigen presented, which can then be analyzed using flow cytometry. The T cells must, in 
addition to recognizing the presented antigen, be able to recognize the specific MHC 
haplotype of the tetramers. It is therefore necessary to determine the haplotype of the T cells 
before conducting this test[95]. 
 Staining cells 
Staining cells with fluorochrome-conjugated antibodies for flow cytometry was done in 
accordance to a general procedure described the BD Biosciences webpage[96]. 100-200μL 
cell suspension containing at least a few hundred thousand cells was spun down at 1700rpm 
for 5 minutes. The supernatant was flicked of, and the cells are resuspended in 50μL staining 
buffer containing an appropriate amount of fluorochrome-conjugated antibody. The cells were 
left in the dark at room temperature for 20 minutes. After incubation, 100μL (for microwell 
plates) or 1mL (for FACS tubes) staining buffer was added, and the cells are spun down. The 
cells were then washed twice by adding 100μL/1mL staining buffer, spun down, and the 
supernatant discarded. The cells were then fixed by re-suspending in 100μL 
paraformaldehyde. The staining panels used for B and T cell cultures are shown below. 
B CELL FLUORESCENT MARKER PANEL 
MARKER Fluorophore Manufacturer 
CD45RO Alexa Fluor 488 BioLegend 
CD45RA Brilliant Violet 421 BioLegend 
CD80 APC-Cy7 BioLegend 
CD86 Brilliant Violet 605 BioLegend 
CD19 PE-Cy7 BioLegend 
HLA-DR (CLASS II) Alexa Fluor 700 BioLegend 
HLA-ABC (CLASS I) PE Antibodiesonline.com 
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T CELL FLUORESCENT MARKER PANEL 
MARKER Fluorophore Manufacturer 
CD4 BV 421 BioLegend 
CD8A BV 785 BioLegend 
CD3 PE BioLegend 
CD45RO Alexa Fluor 488 BioLegend 
CD62L BV605 BioLegend 
CD45RA APC/Cy7 BioLegend 
 
2.2.1 Tetramer staining 
The protocol for staining cells with tetramers was performed in a similar way to staining with 
fluorochrome-conjugated antibodies. The only difference was a preparation step needed to 
make tetramers from MHC monomers, by assembling them on streptavidin. Class I MHC 
monomers refolded with specific 9mer peptides were obtained from the Jianhong Cao 
(Immune Monitoring Lab, Fred Hutchinson Cancer Research Center, Seattle Washington). 
0,5µg/µL monomer/well on a 96 well plate was mixed with 0,75µg/µL streptavidin. PBS was 
added so the total volume amounted to enough for 5µL mixture per well to be stained. The 
mixture was then incubated for 30minutes at room temperature in the dark. 5µL of the 
tetramer solution was then added to each well to be stained. The rest followed the same 
procedure as for staining with antibodies. 
 Cell lines 
2.3.1 NIH-3T3 tCD40L 
Immortalized murine fibroblast cell line that is often used to provide growth factors to the 
cells they are coincubated with. The particular line used in this project provides CD40 ligand 
(CD40L), also known as CD154 to B cells[97]. CD40L binds to CD40 on B cells, which 
promotes their maturation, and regulates many important processes, including 
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immunoglobulin class switching, and formation of germinal centers[98]. Of particular 
importance, interaction with CD40L provides a resting B cell with a stimulatory signal that 
activates it and primes it for antigen presentation. This signal is normally acquired through 
interaction with T cells, but by using the feeder cell line as a co-culturant, the process is 
streamlined. IL-4 is provided to the culture, which causes up regulation of MHC class II 
expression and proliferation of the B cells[29], making them ideal for cross-presentation to 
CD8+ T cells. 
2.3.2 NK cell lines 
Several different NK cell lines exist, isolated from NK lymphomas that represent various 
stages of NK cell differentiation. These lines provide an excellent opportunity to test the 
cytotoxicity of NK cells at different education stages. 
NK92 
NK92 is an NK cell line characterized by a CD56bright phenotype, and a lack of inhibitory 
receptors such as KIR, as well as a lack of expression of the Fc receptor CD16[99]. This is a 
stage of differentiation relatively early in NK cell education, and cells with this phenotype is 
generally thought of as having low cytotoxicity, but capable of secreting a large amount of 
stimulatory cytokines, primarily interferon-γ (IFN-γ). 
NKL 
A cell line established from large granular lymphocyte leukemia[100], with a CD56dim CD16+ 
phenotype, and expresses the inhibitory receptor CD94/NKG2[101]. This is charachteristic of 
a more mature state of differentiation.  
 Cytotoxicity assay 
The adherent melanoma cell line FemX-V was killed using the NK cell lines NKL and NK92. 
A total of 9.5x107 FemX cells were killed in two separate tubes, using 3.0x107 NK92 in one 
tube, and 15.0x7 NKL in the other. This is an effector:target ratio of  0.3:1 for NK92:FemX, 
and 1.6:1 for NKL:FemX. The cells were suspended in 30mL CellGro GMP CD (CellGenix)  
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serum-free media to avoid serum-derived proteins and proteases in the supernatant. The tubes 
were then incubated at 37°C for 8 hours. After incubation, the tubes were spun down at 
3000rpm for 12 minutes. The supernatant was kept, and protease inhibitors were added. The 
supernatant was then put at 4°C to keep for separation of antigens. 
2.4.1 Time based Degranulation assay 
To monitor the killing efficiency of the NK cells versus the target, a degranulation assay was 
set up to monitor expression of CD107a in the effector cells over time. 100μl of effector and 
target was pipetted into 10x2 wells on a 96 well plate. Anti-human CD107a antibody (BD 
Pharmingen, Alexa Fluor 700) was added to the effector cells at a concentration of 1:50. The 
effector cells were then transferred into the target well after 0, 1, 2, 3, 4, 5, 6, 7, 7,5, and 8 
hours.   
2.4.1 Fractionation of Lysates 
The lysates generated from NK cell mediated killing of FemX were separated into fractions 
based on their molecular weight. This was done using Amicon Ultra-15 Centrifugal Filter 
(Merck Millipore) 3k and 10k devices. The lysates were first filtered through the 10k device, 
to separate into fractions of peptides above and below 10kDa. This was done by spinning the 
filter tubes at 4000rpm for 15 minutes. The flowthrough from this, containing the fraction 
below 10kDa, was then filtered through the 3k device. The filter tubes were spun at 4000rpm 
for 45 minutes. The flowthrough from this contained the fraction below 3kDa. The unfiltered 
volume left in the tube would then contain the fraction between 3kDa and 10kDa, at a 
concentration of about 50x. All fractions were then frozen down at -80°C.  
 Cell storage 
2.5.1 Freezing cells 
To freeze a cell culture down for storage, the culture was first spun down for 8 minutes at 
1300rpm. The supernatant was discarded, and the cells resuspended in 10mL RPMI 1640 with 
10% FCS and spun down again. This step was done twice, to wash the cells. The supernatant 
was then discarded, and the cells resuspended in 500μL RPMI1640 with 20%FCS. This 
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500μL cell suspension was then transferred into a cryotube. 500μL RPMI1640 with 15% 
DMSO was added dropwise into each cryotube. The vials were then put into -80°C overnight, 
before they were transferred to liquid nitrogen after 24 hours.  
2.5.2 Thawing cells 
To thaw cells for further use, they were taken from the freezer and put on dry ice. A 15mL 
tube containing 10 parts RPMI 1640 medium without serum and 1 part CTL wash was 
prepared. The sample was put at 37°C until it thawed almost fully, only containing a small 
ball of ice. 500μL of the washing media solution was then added drop wise into the sample. 
The sample was then pipetted drop wise from the sample vial into the media tube in lots of 
500μL, until the entire sample was transferred. The cells were then spun down at 1500rpm for 
5 minutes, resuspended, washed with 1 part CTL wash and 10 parts serum free RPMI 1640 
medium, and spun down again at 1500rpm for 5 minutes. They were then resuspended in 
RPMI 1640 medium with 10% FCS, and either used or stored at 37°C and 5%CO2. 
 Culturing CD40 activated B cells 
CD-40 activated B cells to be used as APCs were generated as outlined in [102], with a few 
modifications. The B cells themselves were isolated from fresh blood or thawed PBMCs 
using AutoMACS magnetic separation.  
2.6.1 AutoMACS separation 
Isolation of B cells was done from thawed PBMCs, on the Miltenyi Biotech 
AutoMACS/AutoMACS Pro machines, following the Miltenyi provided protocol at their 
website[103]. The cells were counted, and spun down at 300xg for 10 minutes. The pellet was 
then resuspended in 80µL AutoMACS buffer per 107 total cells. On the AutoMACS Pro, the 
machine does the remaining steps. For the AutoMACS, it was done manually. 20µL CD19 
Microbeads (Miltenyi Biotech) per 107 total cells was added, and mixed. The cells were then 
put at 4° for 15 minutes to incubate. After incubation, 1-2mL AutoMACS buffer per 107 cells 
were added, and spun down at 300xg for 10 minutes. The supernatant was discarded, and the 
cells were resuspended in 500µL AutoMACS buffer, now ready to be separated by positive 
selection on the AutoMACS. 
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 B cell culture 
B cells were expanded in 6 well plates, using NIH-3T3 cells expressing CD40L as feeder 
cells. First, feeder cells were irradiated, and a 2mL suspension was placed into the wells at a 
density of 0.1 x 106 /mL, for a total of 0.2 x 106 cells/well. The plates were then incubated for 
at least 4 hours, to allow the feeder cells to become adherent. The medium used was 
Dulbeccos Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum (FBS) and 0,1% 
gentamicin.  
Isolated B cells were suspended in RPMI1640 medium with 10% FBS and 0,1% gentamicin, 
supplemented with 4ng/mL IL-4 and 5µg/mL insulin. The medium from the preincubated 
feeder plates was removed, and replaced with 4ml B cell suspension containing 2 x 105 B 
cells/well. The plates were then incubated at 37°C and 5% CO2 for 7 days. The adherent 
feeder cells were resuspended using 2mM EDTA in PBS. Trypsin was not used, as it had a 
damaging effect on the cells.  
2.7.1 Pulsing with antigen 
Antigen was pulsed onto cultures on day 7 of B cell culturing. Autologous PBMC was thawed 
from nitrogen storage, two fractions were made, one with 4 x 106  PBMC only, and one with 
4 x 106  PBMC and 4 x 106  autologous B cells.  The cells were resuspended in 400µL T cell 
medium (TCM, section 2.8.1). From these two fractions containing cells suspended in 400µL 
TCM, 100µL was dispensed into 4 wells for each tube for a total of 8 wells on a 96 well plate. 
The cells were then pulsed with antigen, by adding 2 µL antigen into each well, and set to 
incubate at 37°C for 60-90 minutes. The 100µL cell suspension in the well were then 
transferred into 10 wells, each now containing 10µL cell suspension. The volume in each well 
was then brought up to a total volume of 200µL with TCM. The plate was then incubated at 
37°C and 5% CO2.  
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2.7.2 Antigenic peptides used to pulse cell cultures 
Epstein-Barr virus (EBV) peptides 
BZLF-1 
BZLF-1 is a transcriptional factor expressed by EBV that initiates disruption of its latent 
period. EBV is a ubiquitous virus that infects over 90% of the world’s population, and is the 
cause of infectious mononucleosis, as well as having the potential to induce various lymphoid 
and epithelial-derived malignancies. BZLF-1 has been shown to be highly 
immunogenic[104], and has been suggested as a potential target for vaccine 
development[105]. 
EBNA-1 
Another EBV protein, EBNA-1 involved in most of the functions of and latency phases of the 
virus. Although the protein is expressed in every phase of the EBV lifecycle[106], it is poorly 
recognized by the immune system due to a low expression level, and terminal Gly-Ala repeat 
sequences that prevents it from proteosomal breakdown and presentation on MHC 
molecules[107]. 
EBV consensus sequence 
A library containing peptides from a consensus sequence of the EBV proteome. 
Cytomegalovirus (CMV) peptides 
PP65 
PP65 is the major constituent of human cytomegelovirus (hCMV) virions, and has been found 
to be a highly recognized target for both humoral[108] and cell-mediated[109] immune 
responses. It has been shown to modulate antigen presentation[110], and to reduce the 
activation of NF-κB[111]. 
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(Self) Tumor antigen 
MART-1 
Melanoma antigen recognized by T cells 1 (MART-1), also known as protein melan-A, is an 
antigenic protein found on the surface of melanocytes[112]. Its expression is a marker for 
melanoma, and is known to be recognized by CD8+ T cells. MART-1 has successfully been 
used in clinical trials to pulse dendritic cells to induce expansion of melanoma specific T cells 
[113]. 
2.7.3 Pulsing with tumor cell Lysate fraction 
Cultures were pulsed the lysate from NK cell killing, obtained from the procedures described 
in 2.4. The 10kDa to 3kDa fraction was used, as this fraction should contain peptide 
fragments of theoretically the right size for antigen presentation. The procedure was the same 
as the one described in 2.7.1, but the medium used for the duration of the pulsing was serum-
free CellGro GMP CD (CellGenix), with lysate in a concentration of 1:5 lysate:medium. The 
cells were then incubated for 60-90 minutes at 37°C. After incubation, the cell suspension was 
pipetted over 10 wells, and added up to a total volume of 200µL with TCM. 
 T cell culture 
T cells were grown from PBMCs and coincubated with B cells from the same donor. This was 
done by transferring 4 x 106 cells (PBMC only, and PBMC + B cells) into two 15mL tubes 
containing either PBMC only, or PBMC + B cells. The tubes were then spun down at 1500rm 
for 5 minutes. Cells were then pulsed with antigen according to the procedure described in 
2.7.1. The next day, 50u IL2 was added into each well, and set back into incubation. The plate 
was incubated at 37°C and 5%CO2 for 7 days.  
On day 7, the 10 wells from each row were pooled together into 1 well on a 12 well plate, 
totaling a volume of 2mL in each well. This volume was brought up to 4mL with TCM. 
Around day 7 was when these T cell cultures started to proliferate heavily, and they were fed 
with new medium every 1-2 days past this point. Refeeding was done by carefully removing 
about half the volume in the well, and then adding the same volume of fresh TCM. Around 
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day 12 was when T cell proliferation reached its peak, so a sample of 200μL from each well 
was taken and prepared for analysis. The rest was frozen down for later use. 
2.8.1 Media and supplements 
 
Interleukin 2 (IL2) Drives the differentiation and proliferation of T cells 
Interleukin 4 (IL4) Induces B cell proliferation, and up regulation of MHCII 
Insulin Boosts metabolism of B cells, stimulating growth 
Media 
Suspension Cells were grown in RPMI 1640 supplemented with 10% Fetal Calf Serum (FCS) 
Adherent cell lines were grown in Dulbeccos Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Calf Serum (FCS) 
T cell medium (TCM) 
The T cell medium (TCM) used to grow T cells was made using RPMI 1640 with 10% human 
serum, supplemented with 1% non essential amino acids (NEAA), 1% sodium pyruvate, 0,1% 
Mercaptho-ethanol (ME), and 0,1% gentamicin. 
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3 Results  
 
 Establishing a B cell APC system for robust T 
cell responses 
CD40 activated B cells were used as antigen presenting cells for this project. B cell cultures 
were established using magnetically purified primary B cells that were co-incubated with the 
feeder cell line NIH-3T3 tCD40L, a murine fibroblast line transfected with CD40L (CD154), 
normally expressed by activated CD4+ T cells. Interaction with CD40L is mediated by CD40 
expressed on the B cell, and the binding of this receptor to its ligand results in activation of 
the B cell[114]. This interaction also causes the CD4+ T cell to secrete IL-4, a cytokine that is 
thought to synergize with CD40L in driving the clonal expansion of B cells[115]. IL-4 was 
therefore added as a supplement to the B cell culture to stimulate expansion in the absence of 
CD4+ T cells. In addition, insulin was also given as a supplement to increase proliferation. 
3.1.1 CD40 activated B cells exhibit a substantial increase in 
CD86 expression 
To assess B cell activation in the primary B cell cultures, a timecourse for CD86 expression 
over seven days in culture with CD40L expressing feeder cells was set up. A sample of 200µl 
cell suspension was stained each day with CD86 antibody (Brilliant Violet 605, BioLegend) 
in a concentration 1:100. A mastermix of staining antibodies was made on Day 0 and used for 
every subsequent day to minimize variance. CD86 (B7-1) is a co-receptor expressed on 
activated B cells, as well as on monocytes. Its function is similar to CD80 (B7-2), namely to 
bind CD28 and CTLA-4 on a T cell, which triggers a co-stimulatory signal necessary for the 
activation and proliferation of naïve T cells[116]. Increased expression of CD86 will 
contribute to a more efficient means of activating T cells, and serves as a marker for B cell 
activation.  
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Figure 5 A representation of the expression of B cell activation marker CD86 over time.  
 
The expression was measured on five donors, with each donor showing a similar curve. Every 
donor reached a peak expression at around day 4-5, after which point the level was maintained 
for the rest of the time period. The B cells were taken out of culture and pulsed with antigen at day 
7. 
 
Figure 5 shows the results. There is a substantial increase in expression of CD86 over the time 
period, a clear indication that the cells acquire an activated phenotype. The B cell protocol I 
followed to grow these cells[102] reports an increase in CD80 and HLA-DR (MHC class II) 
as well, but I was not able to reproduce these results, possibly due to problems with the 
staining. The same paper also reports a substantial increase in B cell numbers after about 10-
12 days of culturing, but as I did not need a large amount of B cells, 7-8 days was sufficient 
for the purposes of the project.  
3.1.2 Activated B cells were co-cultured with autologous 
PBMC and pulsed with antigen peptide libraries to induce 
expansion of T cells. 
 In order to determine the efficiency of the CD40 activated B cells as APCs, I pulsed the cells 
with antigenic peptide libraries, and co-cultured the cells with autologous PBMC to look for 
expansions of T cells. For comparison, PBMC from the same donors was stimulated with the 
same peptides in the same manner, but without B cells. This was done by adding 4x106 
PBMC into each of two tubes, and adding 4x106 autologous B cells into one of these tubes. 
These cells were then resuspended in 400µL T cell medium (TCM, section 2.8.1), a medium 
with supplements meant to enhance T cell proliferation. The 400µL cell suspensions was then 
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dispensed into 4x2 wells on a 96 well plate, for a total of 8 wells with 100µL in each well. 
2µL peptide was added to both the PBMC and the PBMC+B wells, with different peptides for 
each pair. Negative controls were wells without peptide added. Figure 6 illustrates how the 
plates were set up. 
 
Figure 6 Plate set up for pulsing cells with antigen.  
 
Antigen was added in such a way that wells with PBMC and PBMC+B was stimulated with the same 
peptides (peptide 1, 2, 3), as well as a negative control 
The cells were then set to incubate at 37°C for 60-90 minutes. After incubation, 10µL from 
each of the wells were dispensed into the next nine wells in the same rows, resulting in a plate 
with 8x10 wells with 10µL cell suspension in each. Each well was then filled to a total 
volume of 200µL with TCM, and set to incubation at 37°C and 5%CO2 for at 7 days. 50u IL-
2 was added to each well the next day. On day 7, the cells were pooled together and dispensed 
into 12 well plates, with one well for each culture. In the following days, the cultures were 
resuspended by pipetting to prevent too much clumping of cells. 
As this process was repeated several times, various peptides could be used for presentation. 
The peptides used were EBV consensus sequence, EBNA-1, BZLF-1, PP65 and MART-1. 
Out of these five, four of the peptides are of viral origin (EBV consensus, EBNA-1, BZLF-1 
(from Epstein-Barr virus (EBV)) and PP65 (from cytomegalovirus(CMV)). MART-1 is a self 
31 
 
tumor antigen associated with melanoma. Through stimulation with these antigens, I wanted 
to determine to which extent T cells would expand in response, and whether or not co-
culturing with CD40 activated B cells had an impact on magnitude of the expansions. 
 Expansion of T cells in response to antigens 
The rationale behind co-culturing PBMCs with CD40 activated B cells, is that these B cells 
will provide a more efficient means of activating T cells, and thus result in a better expansion 
of effector T cells. To investigate this, a comparison between the cell cultures described in the 
previous section was done by flow cytometry analysis. The cells were stained with antibodies 
for CD3 (PE, BioLegend), CD4 (Brilliant Violet 421, BioLegend) and CD8a (Brilliant Violet 
785, BioLegend). The results were gated in CytoBank by gating gating side scatter area (SSC-
A) vs. forward scatter area (FSC-A) on the population with the size properties of PBMC, then 
gating on forward scatter area (FSC-A) vs. forward scatter height (FSC-H) to exclude non-
single cells, and then on CD3 positive signal to obtain populations of CD3+ PBMCs. Out of 
the CD3 positive cells, CD4 signal was plotted against CD8 signal to determine the size of 
these populations. In hindsight, a dead cell marker should also have been used, to exclude 
non-specific signals resulting from dead cells in the analysis. Figure 7 shows an example of 
the gating strategy used to determine the CD4+ and CD8+ populations.  
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CD4 (-) EBV EBNA-1 BZLF-1 
PBMC 3371 1946 2738 1163 
PBMC+B 164 286 304 695 
CD8 (-) EBV EBNA-1 BZLF-1 
PBMC 879 701 876 865 
PBMC+B 103 188 167 576 
 
Figure 7 Example of the gating strategy used for analysis of T cell expansions.  
 
a) Side scatter area (SSC-A) vs Forward scatter area (FSC-A) plot to select PBMCs from the total population of 
cells. Height (FSC-H) vs Area (FSC-A) to select single suspension cells. CD3 plot to select CD3+ cells (should 
be mostly T cells). Out of the CD3+ population, CD4 was plotted against CD8 to determine their counts. b) 
Contour plots of the cultures from one donor, with the cultures not stimulated with B cells (PBMC) in the upper 
row, and the cultures co-incubated with activated B cells (PBMC+B) in the lower row. The cultures have been 
stimulated with the same antigens (EBV consensus, EBNA-1 and BZLF-1). The negative control cultures (-) 
has not been stimulated with any peptide. The event counts of the plots are shown in the table below them. 
  
a) 
 
b) 
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To determine the extent of the T cell expansions, I first tried to look at the percentages of the 
resulting CD4+ and CD8+ cells. This turned out to be a non-optimal way of analysis, as the 
percentages did not really say much about whether or not an expansion had occurred, and it 
was confounded by the effect that percentage shift in one cell type affecting the other. It gave 
some indication about to what degree non-differentiated, double positive cells became 
differentiated as a result of being exposed to the antigen, but was not a very helpful way of 
determining if an expansion of effector cells were actually occurring.  
A better way of looking for expansion was to look at the differences in the event count for the 
populations, as shown in Figure 7. Each well analyzed by flow cytometry was run in its 
entirety, giving comparable relative event counts per well between different conditions. The 
event count is simply the number of cells in a certain population, where one event is one cell. 
This should give a more representative view of the expansion of a cell population as a 
response of antigen stimulation. The hypothesis is that cultures stimulated with antigen should 
cause more cells to divide, resulting in more cells if the antigen is recognized, in other words, 
an expansion. Furthermore, if the culture contains CD40 activated B cells, the activation 
should be more efficient, thus resulting in a bigger expansion.  
3.2.1 Co-culturing with CD40 activated B cells results in 
increased T cell expansions  
In a perfect world, all the cultures would contain about the same amount of cells from the 
start, and give rise to about the same amount of events when analyzed, as they all started with 
what should be approximately the same amount of cells. However, the analysis of the 
different cultures showed at times very varied numbers of events from donor to donor, and 
from culture to culture. This variation could result from a lot of potential sources, from start to 
finish of the process, originating either from differences in biology from donor to donor, or, 
maybe more likely, the inexperience of the researcher. Even though every culture was treated 
the same way in theory, in practice there could be differences between certain conditions. 
These include parameters such as the freshness of reagents, health of thawed cell cultures, 
small differences in culture time, care and attention given to growing cultures, ongoing 
infections of the donor at the time of donation, or amount of dead cell debris in culture. 
Taking all this into consideration, the variance of the cell counts could be a result of external 
factors, however, one can only look at the numbers and analyze them as to the best of one’s 
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ability. Even though some donors showed some unexplained variation between cultures, each 
donor seemed to show a more or less consistent pattern after being stimulated with different 
antigens. 
To standardize the magnitude of expansion between donors, fold change was used. Fold 
change is a simple way of showing the degree of change from one value to another, or the “x-
fold” change in event count from one culture to another. The most common way of 
calculating fold change is to divide the final value B, with the initial value A, or 
𝐵
𝐴
. This 
means that a positive change is above 1, and a negative change is between 0 and 1. A 4-fold 
change would mean a B value 4 times higher than the A value, while a 0.25-fold change 
would mean a B value 4 times lower that the A value. Another way of calculating fold change 
would be to take the negative of the inverse of a fold-value below 1, to end up with a negative 
number, in other words, a 0.25 fold change would be a fold change of -4. An obvious 
difference between these two ways of calculating fold change, is that when averaging out 
numbers, negative fold changes have a much higher impact when they are represented as their 
negative fold change, than when they are represented as a number between 0 and 1. This is 
clearly something one must take into consideration when trying to represent these numbers. 
Since I am looking for expansion of populations, I am really only interested in positive fold 
changes. Negative fold changes mean there is no expansion, while positive changes mean that 
there is. I will therefore use the standard way of measuring fold change, with negative fold 
changes represented as numbers between 1 and 0. The fold changes in T cell counts after 
being stimulated with antigen and incubated for 12 days are shown in Figure 8. 
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Figure 8 Graph of expansions in CD4+ and CD8+ T cells, represented by fold change.  
 
Blue color represents cultures not co-cultured with CD40 activated B cells (PBMC), red color represents 
cultures that have been co-cultured with CD40 activated B cells (PBMC+B). The only significant 
differences in CD4+ expansions are for cultures stimulated with EBNA-1 or MART-1 peptides. For the 
MART-1 expansions, there is significant increase for the cultures that have not been co-cultured with 
CD40 activated B cells. In the CD8+ populations, there is a significant increase in expansion for cultures 
pulsed with BZLF-1 peptide. P values were calculated using a paired Students t-test. 
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Figure 8 shows the different T cell expansions represented by their fold change value. 
Cultures co-incubated with CD40 activated B cells (PBMC+B)  are shown as red dots, 
cultures not co-incubated with CD40 activated B cells (PBMC) are shown in blue. The only 
significant increases in T cell expansions are displayed by EBNA-1 for CD4 and BZLF-1 for 
CD8. CD4 expansions for MART-1 actually show a significant decrease in numbers in the B 
cell stimulated cultures. The overall highest expansions are toward the BZLF-1 peptide, with 
CD8+ cells showing the most dramatic response, suggesting that BZLF-1 is highly 
immunogenic. These findings are consistent with the reports of Hartlage et al., who found 
expansions of BZLF1-specific CD8+ after co-culturing autologous PBMCs with dendritic 
cells pulsed with recombinant BZLF1[105]. It is strange that there are no significant 
expansions in the EBV consensus sequence stimulated cultures, as this peptide library 
contains sequences from all EBV proteins. A reason for this could be that the exact peptide 
sequences for the other peptides are not a part of the library, or at least contains a lower 
proportion of the recognized peptide. Overall, the results indicate that co-culturing with CD40 
activated B cells results in better expansion, given that the cultures are maintained properly.  
 Generation of epitope specific T cell responses 
Expansion of T cells come as a result of the clonal selection and proliferation of cells that 
have recognized a specific epitope and been given the signals required to divide and multiply. 
I wanted to investigate the T cell expansions to determine what percentage of the populations 
was epitope specific for the peptide they had been pulsed with. In order to assess this 
question, the populations were stained with tetramers. Tetramers are tetrameric molecules 
made up of MHC monomers complexed with antigen, bound together by streptavidin and 
marked with fluorescent labels. T cells specific for the peptide complexed with the MHC 
molecules are able to bind the fluorescent tetramers, and will show up as a positive signal in a 
flowcytometric analysis. In order for the cells to be able to bind the MHC molecules, they 
need to be of a matching haplotype, so donors need to be screened for the specific haplotype 
of the tetramers before staining.  
3.3.1  CD8+ T cell specific expansions towards PP65 antigen 
 A tetramer stain was used to test the specificity of the expanded T cells. The tetramers were 
of the HLA-A2 haplotype, so in order to assess the specificity of the cells, donors of this 
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haplotype were needed. A simple screen on eight donors, using anti-human HLA-A2 
(eBioScience, Pe-Cy7) was set up to identify A2 positive samples. The results of this screen 
are shown in Figure 9. 
 
Of these eight donors, four were identified as positive, and four were identified as negative, 
based on comparison to an unstained control. The cells were pulsed with peptides from PP65, 
MART-1 and BZLF-1 in the same manner as described in 3.1.2. The cells able to recognize 
the antigen presented on the tetramer, will bind the tetramer, and manifest as a positive signal 
on a flow cytometry dot plot. The percentage of cells specific for the tetramer were compared 
to the negative control, by gating for events trailing off from the main population. An 
example of this is shown in Figure 10 
Figure 9 The result of the screen for HLA-A2 positive donors.  
 
Donors 202, 203, 204, and 206 were identified as HLA-A2 positive. 
38 
 
 
Figure 10 Tetramer stains of donor 206. 
 
The dotplots show how the tetramer positive cells trail off from the main population. 
 
 
 
 
 
  202+ 203+ 204+ 205- 207- 206+ 209- 210- 
PBMC (-) 7,50 % 5,19 % 6,05 % 3,74 % 6,45 % 6,00 % 5,33 % 6,66 % 
PBMC PP65 6,00 % 9,21 % 35,60 % 6,74 % 7,87 % 30,26 % 5,83 % 8,19 % 
PBMC MART-1 7,18 % 7,14 % 5,89 % 7,09 % 9,81 % 8,47 % 3,34 % 5,07 % 
PBMC BZLF-1 6,06 % 5,78 % 4,28 % 9,51 % 6,86 % 9,38 % 1,84 % 3,58 % 
P+B (-) 4,47 % 4,87 % 4,69 % 6,54 % 5,02 % 4,04 % 2,91 % 4,99 % 
P+B PP65 7,59 % 4,30 % 56,96 % 7,56 % 10,00 % 36,71 % 0,20 % 1,08 % 
P+B MART-1 6,21 % 4,27 % 4,24 % 3,84 % 2,98 % 9,48 % 0,00 % 2,31 % 
P+B BZLF-1 10,39 % 4,02 % 3,83 % 5,05 % 4,55 % 5,39 % 0,42 % 2,25 % 
 
Table 1 Percentages of tetramer positive CD8 T cells. 
 
Donor numbers are shown as HLA-A2 positive or negative (e.g. 204+, 205-). Donors 204 and 206 show a 
strong response to the PP65 tetramer, with minimal response towards the other tetramers. None of the HLA-
A2 negative donors show any response.  
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Table 1 Percentages of tetramer positive CD8 T cells.sums up the results of the tetramer 
stain. Two donors, 204 and 206, show an obvious response to PP65, with no response to any 
other antigen. The HLA-A2 negative donors does not respond to any of the tetramers, as 
expected. None of the donors shows any strong signal from the BZLF-1 tetramer, even though 
BZLF-1 stimulated cultures had the highest CD8+ expansions. This could either stem from a 
problem with the BZLF-1 tetramer, or it could be that the expanding cells are recognizing 
another epitope than the one presented on the tetramer.  
 Generation of NK derived cytolytic fragments for 
antigen presentation 
Having established that B cells co-culture results in greater specific T cells expansion, I then 
proceeded with investigation into whether lysates derived from cytolysis of tumor cells could 
produce specific T cell expansions. The lysates were obtained by NK cell driven cytolysis of 
the tumor cell line FemX, with the NK cell lines NK92 and NKL as effector cells. A total of 
14.25x107 FemX cells were used in the experiment, split equally into 3 tubes resulting in 
4,75x107 FemX cells in each tube. 3.0x107 NK92 cells were added into one of the tubes, 
15.0x107 NKL were added into the other tube, giving an effector:target ratio of 0.3:1 
NK92:FemX and 1.6:1 NKL:FemX. The remaining tube containing FemX only, was kept to 
provide a negative control. The cells were suspended in 30ml CellGro GMP CD (CellGenix)  
serum-free media to avoid serum-derived proteins and proteases in the supernatant. These 
tubes were then set to incubate at 37C for 8 hours and a time based degranulation assay was 
set up to monitor NK cytotoxicity over the same time period. The next section will describe 
the results of the degranulation assay. 
3.4.1 NKL exhibits a stronger degranulation than NK92 versus 
FemX  
A degranulation assay was set up as described in 2.4.1 to assess the cytotoxicity of the NK92 
and NKL NK cell lines versus the FemX target cell line. The FemX cell line has been 
tranfected with a plasmid that makes the cell express YFP when alive, and CFP when killed. 
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The experiment was conducted by adding the NK cells to wells at regular time points over 8 
hours, to observe changes in CD107a expression over time. CD107a expression correlates 
with both cytokine secretion and NK cell mediated lysis of target cells, and is therefore used 
to measure NK cell cytolytic activity[117]. The results were analyzed in CytoBank, by first 
gating for YFP negative cells to eliminate target cells from the analysis, then forward scatter 
height vs forward scatter area (FSC-H vs FSC-A) to select for single suspension cells. Out of 
this population, the PBMC population was gated on a FSC-A vs side scatter (FSC-A vs SSC-
A) plot. The %CD107a expression on this population was then assessed on a histogram plot. 
The gating strategy is shown in Figure 11. 
 
Figure 11 Gating strategy for the CD107a degranulation assays. 
 
YFP positive cells are first gated away to eliminate target cells. Next, single suspension cells are 
gated on a FSC-A vs FSC-H plot. Out of the single cells, PBMCs are gated on a FSC-A vs SSC-A 
plot. Histogram plots are then used to assess the % expression of CD107a. 
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Figure 12 Results of the degranulation assays. 
 
The graphs show the change in expression levels of CD107a over a time period of 8 hours. NKL exhibits 
a clear increase in degranulation, peaking out at about 10%, while NK92 shows no increase in 
expression of CD107a. 
 
The results are shown in Figure 12. NKL exhibits a marked increase in degranulation over 8 
hours peaking out at around 10%, with the highest increase between the 0,5h-4h marks. NKL 
has a more mature phenotype, CD56dim CD16+ CD94/NKG2+ [101, 118] associated with 
higher cytotoxicity, consistent with these results. CD56dim CD16+ cells comprise the majority 
of NK cells found in human PBMC. CD16 being FCγ receptor III, these cells are able to bind 
the Fc portion of IgG and thus are capable of mediating antibody dependent cell-mediated 
cytotoxicity (ADCC)[119].  
Also immediately obvious from these graphs, is that NK92 does not seem particularly 
effective at killing the target. This differs from the literature, which mostly seems to agree 
that NK92 is a highly efficient killer [99, 120-123], and the low cytotoxicity observed in this 
data could possibly be a result of the low effector:target ratio used in this experiment (0,3:1). 
However, NK92 has a CD56bright phenotype, a low expression of inhibitory receptors, and no 
expression of CD16. NK cells with these characteristics are generally considered to have a 
low cytotoxicity [119, 124]. The low degranulation exhibited by NK92 cells in my data could 
be a result of this, but it could also be an effect of keeping them in a state of continuous 
culture, which tends to have a negative effect on the cytolytic capacity of NK cell lines. 
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3.4.2 CD40 activated B cells has a significant effect on CD8+ T 
cell expansions pulsed with lysate resulting from NK cytolysis 
An important aspect of this project was to determine to what degree cytolysis by NK cells 
affect T cell responses. To assess this question, I used the lysate obtained from the NK 
cytotoxicity assay described in the previous sections (3.4) to pulse cultures of PBMC and 
PBMC+CD40 activated B cells. The lysates of NKL+FemX and NK92+FemX were used, as 
well as the lysate of the FemX only culture described in section 3.4. The lysates were sorted 
into fractions containing peptides of 3kDa-10kDa through the use of Amicon Ultra-15 
Centrifugal Filter (Merck Millipore) 3k and 10k devices. The lysates were first filtered 
through the 10k device, to separate into fractions of peptides above and below 10kDa. This 
was done by spinning the filter tubes at 4000rpm for 15 minutes. The flowthrough from this, 
containing the fraction below 10kDa, was then filtered through the 3k device. The filter tubes 
were spun at 4000rpm for 45 minutes. The flowthrough from this contained the fraction 
below 3kDa. The unfiltered volume left in the tube would then contain the fraction between 
3kDa and 10kDa, at a concentration of about 50x.  
The reasoning behind using the fraction of peptides with molecular weights of 3kDa-10kDa is 
that these should contain peptides of the ideal size for antigen presentation. Pulsing of the 
cultures was done in much the same was as when pulsing with peptide libraries as described 
in section 3.1.2, but the medium used for the duration of the pulsing was serum-free CellGro 
GMP CD (CellGenix), with lysate in a concentration of 1:5 lysate:medium. The cells were 
then incubated for 60-90 minutes at 37C. After incubation, the cell suspension was pipetted 
over 10 wells, and added up to a total volume of 200µl with TCM. The fold changes of the T 
cell expansions that resulted from this are shown in Figure 13. 
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While the CD8+ expansions are not exceptionally high (they ranged from 1,0 to 2,5 fold 
change for the NKLvsFemX lysate), they do show a marked increase going from the FemX 
lysate to the NK92vsFemX, and the highest expansions for cells pulsed with NKLvsFemX 
lysate. This is in line with the results from the degranulation assay in 3.4.1, which showed a 
very low CD107a expression on NK92 cells towards FemX, and a higher CD107a expression 
for NKL. The higher cytotoxicity associated with the higher CD107a expression on NKL 
would result in more peptide fragments available for presentation, and thus lead to better T 
cell responses. If NK cell lysis fragments contribute to T cell responses, these results are what 
one would expect to see. 
The non B cell cultures interestingly all show a similar median decreased fold change 
compared to the negative control (FemX: 0,6170 ± 0,08585, n=8, NK92+FemX: 0,6477 ± 
0,09239, n=8, NKL+FemX: 0,5914 ± 0,07401, n=8). Why is this? A possible reason could be 
that there is some kind of immunosuppressive factor from the FemX cells present in the cell 
lysate. Melanoma cells have been shown to exploit several mechanisms to suppress immune 
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Figure 13 Shows expansions of CD8+ T cell pulsed with FemX lysate.  
 
B cells have a significant effect on the expansions in all cultures, and non B cell cultures show a 
decrease in T cell counts. 
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responses, such as down regulation of tumor associated antigens[125], various immune 
activating cell receptors like MHC class I[126], co-stimulatory molecules[127], and NK cell 
receptor ligands[128]. In addition, melanoma cells exhibit an intense secretion of 
immunosuppressive factors such as VEGF, TGF-β, IL-10, nitric oxide (NO), and 
prostaglandins [127, 129, 130]. These immunosuppressive factors could have been a part of 
the lysate, and thus caused a suppressive effect on the cells. However, the secreted agents 
mentioned have a molecular weight that should exclude them from the 3kDa-10kDa lysate 
fraction. Nonetheless, there does seem to be some kind of suppressive effect present. This 
suppressive effect is only apparent in the non B cell stimulated cultures, indicating that the 
CD40 B cells somehow counteract this suppression. 
3.4.3 Pulsing with melanoma cell lysate induces expansion of 
MART-1 specific CD8+ T cells 
The same donors from section 3.3.1 was pulsed with the NK cell lysates of the melanoma line 
FemX as described in section 3.4.2. This caused expansions of CD8+ T cells co-cultured with 
CD40 activated B cells (3.4.2), so I wanted to investigate if these expansions were specific 
towards the MART-1 antigen, a melanoma associated protein expressed by FemX. To answer 
this question, the cell cultures were stained with MART-1 specific pentamers (Proimmune, 
UK), and gated in the same manner as described in section 3.3.1. 
  202+ 203+ 204+ 205- 206+ 207- 209- 210- 
PBMC (-) 2,81 % 4,74 % 5,35 % 5,48 % 5,49 % 6,00 % 5,12 % 3,43 % 
PBMC FemX 3,44 % 10,49 % 7,03 % 2,35 % 2,51 % 3,04 % 2,85 % 1,54 % 
PBMC NK92+FemX 5,00 % 8,53 % 10,24 % 7,23 % 4,95 % 4,75 % 3,78 % 2,02 % 
PBMC NKL+FemX 6,74 % 9,58 % 10,96 % 4,06 % 5,40 % 2,16 % 5,85 % 6,70 % 
PBMC+B (-) 2,79 % 6,53 % 5,47 % 2,97 % 3,40 % 3,99 % 4,33 % 4,70 % 
PBMC+B FemX 5,26 % 6,55 % 4,07 % 8,22 % 4,51 % 5,21 % 3,74 % 6,93 % 
PBMC+B NK92+FemX 8,33 % 15,36 % 3,22 % 7,98 % 5,98 % 8,22 % 2,75 % 9,97 % 
PBMC+B NKL+FemX 8,77 % 18,02 % 8,47 % 7,29 % 16,15 % 12,25 % 10,20 % 32,12 % 
 
Table 2 Percentages of MART-1 tetramer specific CD8+ T cells 
Table 2 shows the results. The highest responses are from the cells co-cultured with B cells, 
and highest of those, are the cells pulsed with the NKL+FemX lysate. Because NKL had the 
highest degranulation versus FemX, these results support the hypothesis that NK cell 
mediated cytotoxic activity improves the responses of the adaptive immune system. A very 
striking observation here is that the strongest response is from donor 210. This donor was 
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identified as A2 negative, and therefore should not be able to bind to the tetramers. A possible 
explanation for this could be experimental error; however, it is possible that this donor is of a 
haplotype that is not A2, but a similar haplotype that is able to crosslink A2 specific 
tetramers. A DNA test of the donor would be required to confirm this.  
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Figure 14 MART-1 tetramer specific CD8+ T cells.  
 
 A) Comparison between MART-1 specific CD8+ T cells with and without B cells in co-culture. B) A 
comparison of the MART-1 specific CD8+ T cells in cultures that was co-cultured with B cells. P-values 
was determined by a paired Students t-test. 
The data is shown in Figure 14. I wanted to see if co-culturing with B cells would have a 
significant effect on the amount of MART-1 specific CD8+ T cells induced. This can be seen 
in A). The figure shows that there is a significant difference (P=0,0357) between the 
stimulated and non-stimulated cultures pulsed with the NKL+FemX lysate, but not for the 
other lysates. NKL was the NK cell line with highest cytotoxicity towards FemX, and the 
observation that this lysate produced the highest amount of MART-1 specific T cells supports 
the hypothesis that NK cell mediated lysis produces antigenic fragments that improve 
adaptive immune responses. To further back up this hypothesis, I compared the amount of 
MART-1 tetramer specific CD8+ T cells in the different cultures co-incubated with B cells. 
This is shown in Figure 14 B). This figure has a similar pattern to the CD8+ T cell expansions 
shown in Figure 13 in 3.4.2, where FemX only lysate has a small effect, NK92+FemX has a 
higher effect, and NKL+FemX lysate has the highest effect.  
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3.4.4 MART-1+ tetramer specific CD8+ T cells are 
predominantly central memory cells 
The adaptive immune compartment is a highly efficient system capable of remembering 
previously encountered threats, which will be eradicated faster and more efficiently than in 
the first exposure to the same threat. This is the mechanism behind vaccination, in which a 
harmless agent resembling a pathogen is injected into the body, to activate an immune 
response toward this pathogen. The agents responsible for this are memory cells, long-lived 
immune cells that have recognized the pathogen, become activated, and then kept after the 
infection has been fought off. These cells are then ready to immediately start fighting off the 
threat again if it should come back, without the need for going through the process of 
activation from APCs. The cell markers used in this project to identify memory populations 
are CD45RO, CD45RA, and CD62L. Naïve T cells express CD45RA, which they will lose 
after antigen experience, and start expressing CD45RO as they change to a memory cell 
phenotype. CD62L is a lymph node homing receptor, expressed by naïve T cells and central 
memory T cells that enables the cells to migrate to secondary lymphoid organs. Effector cells, 
both memory and non-memory, do not express CD62L which allows them to accumulate in 
peripheral tissues[131].  
 
Figure 15 Determination of differentiation state of MART-1 tetramer+ CD8+ T cells. 
 
The MART-1 specific cells are predominantly CD45RO+ CD45RA-, indicating a memory phenotype. 
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Figure 15 shows the flowcytometric analysis of the MART-1 positive CD8+ T cells in the 
donors with highest responses. The cells are predominantly CD45RO+/CD45RA-, indicating a 
memory cell phenotype. To further investigate the phenotype of the MART-1+ cells, the 
expression levels of CD62L were measured and compared to the MART-1- population. 
Analysis dot plots are shown in Figure 16. The majority of the cells, both positive and 
negative for the MART-1 tetramer, are CD62L+. A CD45RO+ CD62L+ phenotype is 
characteristic of central memory T cells (TCM), experienced T cells that have little or no 
effector functions, but home to lymph nodes to proliferate and differentiate into effector cells 
in response to antigen encounter[131].  
The level of CD62L is equal between MART-1+ and MART-1- cells in donors 203 and 206, 
however in donor 210 there is a slight decrease in expression in the MART-1+ population, 
indicating a higher percentage of effector memory T cells (TEM). These are antigen 
experienced cells that are able to display immediate effector functions in response to 
antigen[131].  
 
Figure 16 Levels of CD62L expression in the MART-1 positive and negative CD8+ populations. 
 
The majority of cells are CD45RO+ CD62L+, characteristic of central memory T cells (TCM). A slight shift 
towards a lower expression of CD62L can be seen in the MART-1+ population of donor 210.  
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4 Discussion 
The goal of this project was to investigate the connection between NK cell mediated cytolysis 
and adaptive immune responses, and as a part of this investigation I made use of CD40 
activated B cells to improve the presentation of pathogen specific antigen. The B cells showed 
an increased expression of the activation signaling receptor CD86 after co-culturing with 
CD40L expressing feeder cells, indicating progression toward an activated phenotype. The B 
cells did not however, show an increased expression of CD80 and MHC class I and II . This 
contradicts the expected outcome, and the reports of the protocol[102]. This deviation from 
expectation can probably be attributed to experimental errors though, and repeated 
experiments under optimal conditions might show results more in line with the reports.  
Nevertheless, CD40 activated B cells proved to be efficient for expanding antigen specific T 
cells, albeit only for a few of the antigens tested, and of these antigens, only BZLF-1 
stimulated CD8+ cells showed a very significant difference between cultures. BZLF-1 is 
known to be highly immunogenic [132], so this observation is in agreement with previous 
reports.  
The observation that CD8+ T cells are expanding in response to antigens in culture, and the 
strongest expansions are for cells co-cultured with CD40 activated B cells, is a demonstration 
of cross-presentation by these B cells.  Naïve CD8+ T cells require signaling from interaction 
with MHC class I to become activated and expand. MHC class I generally present 
endogenous antigens, and would thus normally require the cell to be infected to activate CD8+ 
T cells. The ability of APCs to cross-present exogenous antigens picked up from outside the 
cell on MHC class I is responsible for the observed activation of CD8+ T cells. Cross-
presentation is usually associated with dendritic cells[133], and the feasibility of their use in 
expanding immune responses in vivo has been well documented[134-137]. However, 
difficulties in growing dendritic cells in vitro, as well as the requirement to use them at a 
specific stage of differentiation to generate protective T cell responses as opposed to 
regulatory or anergic responses[138-140], have led to the suggestion of using other APCs as 
an alternative to DCs. This project uses CD40 activated B cells as an alternative APC, and 
these results indicate the feasibility of this approach. 
To test the hypothesis that NK cell mediated cytolysis generates antigenic epitope for efficient 
presentation to the adaptive immune system, the NK cell lines NK92 and NKL were used as 
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effector cell against the melanoma line FemX. A degranulation assay was set up to assess the 
cytotoxicity of the NK cell lines versus this target. NK92, a cell line characterized by a 
CD56bright CD16- and low expression of inhibitory receptors, proved to be an inefficient 
effector towards these cells. Although touted as a highly efficient killer [99, 120, 141], the 
receptor expression of NK92 indicates an immature phenotype that is not associated with high 
cytoxicity[57]. Conversely, the more mature CD56dimCD16+ CD94/NKG2+ cell line NKL 
showed a higher cytotoxicity towards FemX, consistent with the view that cells with this 
phenotype are more efficient killers. 
The lysate obtained from the NK cell cytolytic activity was then pulsed onto cell cultures. The 
B cells seemed to have a significant effect on T cell responses in this experiment. While 
FemX and the FemX+NK92 lysate did not result in high expansions, the non B cell stimulated 
cultures showed a significant decrease in T cell numbers, an indication that there might have 
been an immunosuppressive agent released from FemX present in the lysate. The CD40 
activated B cells seemed to counteract this effect. As opposed to NK92, the more mature cell 
line NKL showed an increase in degranulation towards FemX. The lysate obtained from 
NKL+FemX proved to have a high impact on CD8+ T cells, resulting in a significant 
expansion compared to the negative control. The higher degranulation exhibited by NKL 
versus FemX seemed to have increased the amount of antigenic peptides available for 
presentation, and thus improved the adaptive response.  
Tetrameric stains of the expanded CD8+ cells revealed a significant improvement in MART-1 
specific T cells in the populations pulsed with FemX lysate. Again, the NKL+FemX lysate 
proved to be the most efficient for inducing antigen specific cells, and again co-culturing with 
B cells improved these responses. The donor with the highest response to the MART-1 
tetramer was a donor typed as HLA-A2 negative. As the tetramer was A2 specific, this 
response is an indication that perhaps the donor is of a haplotype that is able to crosslink 
HLA-A2, however, the DNA test required to confirm this was not ready before the 
finalization of the project. The response could also have been an anomaly.  
The MART-1 tetramer positive cells was predominantly of a memory cell phenotype, 
characterized by a CD45RO+ CD45RA- expression pattern. Of these, the majority were also 
positive for the lymph node homing receptor CD62L, an indication of a central memory (TCM) 
phenotype. One donor, 210, which had the strongest response to the MART-1 tetramer, 
showed a slight downregulation of CD62L in the MART-1+ T cell population, indicative of a 
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shift towards an effector memory cell phenotype(TEM). Previous studies report that melanoma 
patients with TEM cell positive for MART-1 (melan-A) positive cells had clear responses to ex 
vivo stimulation with MART-1[142, 143]. These findings indicate that the cells should be 
tumor reactive. While the majority of the MART-1 tetramer specific T cells where CD62L 
positive, this could come as a result of possible upregulation of CD62L during proliferation, 
and thus be an exaggeration of the amount of TCM. 
While outside the scopes of this project, a more detailed characterization of the adaptive 
responses to the FemX lysate would be an interesting project in itself. Analysis of recognized 
epitopes could perhaps reveal novel melanoma antigens, a promising prospect for future 
immunotherapies.  
In conclusion, the research performed have produced results that seem to confirm the 
hypothesis that NK cell mediated cytolysis produces peptides able to induce efficient adaptive 
immune responses, acting as a mediator between the innate and adaptive compartments of the 
immune system. 
 Cell handling: A lesson in care 
Something that became apparent during this project is the importance of how to handle 
growing cell cultures. Caring for cells is a subtle topic that is difficult to quantify in protocol, 
and is an acquired skill that can only be learned through experience. Yet, operator-dependent 
differences are huge, even if the described protocol has been followed. This section has 
therefore been added to describe the lessons learned over the course of the project.  
One of the difficulties in growing cells, is to avoid accidently killing them. This seems 
obvious, but avoiding it is more difficult than it appears, simply because cells can not be seen 
with the naked eye. Rough handling, like pipetting, can cause fragile cells to die. 
Contaminations that are difficult to see can cause cells to die. Too low cell density can cause 
low growth, and too high density can cause clumping of cells, leading to lack of access to 
nutrients, which will cause the cells to die. To put it simply, there are many ways to kill a cell, 
and avoiding it is difficult and comes down to experience. Avoiding contaminations can for 
the most part be avoided by working in sterile conditions, and by being careful not to expose 
the cells to air outside the cell bench. Obviously, changing pipette tips for each well 
containing different cultures is a given. Keeping medium sterile and contamination free is of 
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huge importance. Still, following these rules, contaminations do sometimes happen, and it is 
important to be able to recognize a contaminated culture, so it can be thrown away to avoid 
contaminating other cultures. 
Dense cultures containing a lot of cells, will clump together if left alone for too long. For this 
reason, it is important to resuspend the culture by mixing it with a pipette, to allow all, or at 
least most of the cells access to nutrients. My first attempts at growing T cells were 
unsuccessful, probably because I did not resuspend them enough. In addition, refeeding cells 
fresh media by throwing away half the volume of the culture and adding in new media is 
important to avoid a depletion of nutrients in the culture. Careful removal of media before 
resuspension of cells is necessary to avoid throwing away too much of the cells. 
Another difficulty becomes apparent when transferring cell cultures between plates or test 
tubes. Cells will tend to stick to the plastic of a plate well or tube, making it important to 
thoroughly resuspend with a pipette to transfer as much of them as possible. Failure to do this 
will lead to transfer of a cull culture without the cells, something which is obviously not 
desirable. Proper pipetting technique is necessary to do this without too much complication. 
In addition to these concerns, there are more small details in regard to technique and 
experience that add up over the course of culturing. My knowledge of maintaining cell 
cultures is far from perfect, but my experiences during the project has taught me very valuable 
lessons that lead to better and clearer results as time progressed. 
 Concluding remarks 
The recent breakthrough in cancer immunotherapy has been paralleled by the insight that the 
immune system recognizes mutated tumor specific antigens, so called neo-antigens, which are 
largely patient specific. Using lysates resulting from NK cell mediated cytolysis mimic the 
naturally occurring bridging of innate and adaptive immunity and release protein fragments 
containing processed neo-antigens for presentation to the immune system. 
The model system used in this project is relatively simple to set up, and can be stimulated 
with peptides from every type of origin, be it of cancer-transformed or infected cells. While 
this project only looked at responses to cytolysis fragments of melanoma cells and MART-1 
specific responses, lysis fragments from other types of cancer or infected cells could be used. 
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A more thorough inspection of the epitopes recognized in expanded T cell populations has the 
potential to reveal a range of neo-antigens that can be used for efficient priming of immune 
responses in the individual patient paving the way for personalized immunotherapy. In order 
to identify new epitopes recognized as a consequence of lysate stimulation, one could isolate 
tetramer positive T cell clones and sequence their TCR. 
Another approach to identifying immunogenic peptides could be further fractionation of the 
tumor cell lysate by using high-performance liquid chromatography (HPLC) to separate finer 
and finer fractions. HPLC is a way of separating the components of a complex sample in 
order to identify and quantify each component present. In this manner, peptides can be 
isolated in order to test the reactivity towards it, which could potentially lead to the discovery 
of novel antigens that can be synthesized for use in vaccines. 
All in all, this projects describes an efficient and relatively simple system to study the priming 
of adaptive immune responses after stimulation with antigenic peptides. Antigens obtained 
through NK cell mediated cytolysis proved to be effective for expanding T cell responses, a 
strategy that could provide an efficient means in the development of new vaccines.  
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